#$%^&*AU2008201395B220130815.pdf#####ABSTRACT A short-term sustained drug eluting coating for implantable medical devices is disclosed. The coating comprises a biocompatible matrix and at least one pharmacologically or biologically active agent and releases substantially one of all of 5 its payloads within four to six weeks post-implantation. When a combination of pharmacological agents are incorporated in the disclosed sustained drug eluting matrix of a drug/device combination, at least one agent is preferred to substantially release in a short duration. Medical devices benefiting from such a desired sustained drug eluting coating include drug eluting cardiovascular, peripheral, and 10 neurovascular stents, abdominal aortic aneurysm (AAA) prosthesis, anastomosis shunt, arterial/venous (AV) shunts etc. One embodiment of the invention is a sustained release coating or depot on or in a stent that releases substantially all of it payload for ischemic myocardial injury after a heart attack. The coating may be formed from biocompatible stable and absorbable polymers of natural and synthetic 15 origins. Useful pharmacological agents for inhibiting vascular neointimal growth post-angioplasty that leads to restenosis include macrolide polyenes such as a rapamycin and all its derivatives and analogs； paclitaxel and all derivatives and analogs. Useful agents for other vascular conditions such as vulnerable plaques may comprise anti-inflammatory, anti-proliferative agents, and matrix metalloprotease 20 (MMP) inhibitors. 26/03/08,kn 17213 spcification,301/4 10 12 100 14 0- 18C 12 02 2 0 23c 00 J~O 20 2 .- 30 o o O 230b 0 O FIG. 2
